Kamila Romanowski1, Brett Baumann2, C Andrew Basham3, Faiz Ahmad Khan4, Greg J Fox5, James C Johnston6. 1. Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada. 2. Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 3. Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. 4. Respiratory Epidemiology and Clinical Research Unity, Centre for Outcomes Research and Evaluation, Research Institute of McGill University Health Centre, Faculty of Medicine, McGill University, Montreal, QC, Canada; McGill International TB Centre and Respiratory Division, Faculty of Medicine, McGill University, Montreal, QC, Canada. 5. McGill International TB Centre and Respiratory Division, Faculty of Medicine, McGill University, Montreal, QC, Canada; Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. 6. Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; McGill International TB Centre and Respiratory Division, Faculty of Medicine, McGill University, Montreal, QC, Canada. Electronic address: james.johnston@bccdc.ca.
Abstract
BACKGROUND: Accurate estimates of long-term mortality following tuberculosis treatment are scarce. This systematic review and meta-analysis aimed to estimate the post-treatment mortality among tuberculosis survivors, and examine differences in mortality risk by demographic and clinical characteristics. METHODS: We systematically searched Embase, MEDLINE, and the Cochrane Database of Systematic Reviews for cohort studies published in English between Jan 1, 1997, and May 31, 2018. We included research papers that used a cohort study design, included bacteriological or clinical confirmation of tuberculosis disease for all participants, and reported, or provided enough data to calculate, mortality estimates for people with tuberculosis and a valid control group representative of the general population. We excluded studies that reported duplicate data, had a study population of fewer than 50 people overall, had a follow-up period shorter than 12 months after treatment completion, or had a loss to follow-up of more than 30%. From eligible studies, we extracted standardised mortality ratios (SMRs), or calculated them when the data were sufficient, by dividing the sum of the observed deaths by the sum of the expected deaths. For studies that did not report SMR as their mortality estimate, either mortality hazard ratios or mortality rate ratios were extracted and pooled with SMRs. Random-effects meta-analysis was used to obtain pooled SMRs. Between-study heterogeneity was estimated with I2. This study was prospectively registered in PROSPERO (CRD42018092592). FINDINGS: Of the 7283 unique studies identified, data from ten studies, reporting on 40 781 individuals and 6922 deaths, were included. The pooled SMR for all-cause mortality among people with tuberculosis, compared with the control group, was 2·91 (95% CI 2·21-3·84; I2=99%, pheterogeneity<0·0001). When restricted to people with confirmed treatment completion or cure, the pooled SMR was 3·76 (95% CI 3·04-4·66; I2=95%). Effect estimates were similar when stratified by tuberculosis type, sex, age, and country income category. Causes of mortality were extracted for 4226 deaths that occurred post-treatment, with most deaths attributable to cardiovascular disease (20% [95% CI 15-26]; I2=92%). INTERPRETATION: People treated for tuberculosis have significantly increased mortality following treatment compared with the general population or matched controls. These findings support the need for further research to understand and address the biomedical and social factors that affect the long-term prognosis of this population. FUNDING: None.
BACKGROUND: Accurate estimates of long-term mortality following tuberculosis treatment are scarce. This systematic review and meta-analysis aimed to estimate the post-treatment mortality among tuberculosis survivors, and examine differences in mortality risk by demographic and clinical characteristics. METHODS: We systematically searched Embase, MEDLINE, and the Cochrane Database of Systematic Reviews for cohort studies published in English between Jan 1, 1997, and May 31, 2018. We included research papers that used a cohort study design, included bacteriological or clinical confirmation of tuberculosis disease for all participants, and reported, or provided enough data to calculate, mortality estimates for people with tuberculosis and a valid control group representative of the general population. We excluded studies that reported duplicate data, had a study population of fewer than 50 people overall, had a follow-up period shorter than 12 months after treatment completion, or had a loss to follow-up of more than 30%. From eligible studies, we extracted standardised mortality ratios (SMRs), or calculated them when the data were sufficient, by dividing the sum of the observed deaths by the sum of the expected deaths. For studies that did not report SMR as their mortality estimate, either mortality hazard ratios or mortality rate ratios were extracted and pooled with SMRs. Random-effects meta-analysis was used to obtain pooled SMRs. Between-study heterogeneity was estimated with I2. This study was prospectively registered in PROSPERO (CRD42018092592). FINDINGS: Of the 7283 unique studies identified, data from ten studies, reporting on 40 781 individuals and 6922 deaths, were included. The pooled SMR for all-cause mortality among people with tuberculosis, compared with the control group, was 2·91 (95% CI 2·21-3·84; I2=99%, pheterogeneity<0·0001). When restricted to people with confirmed treatment completion or cure, the pooled SMR was 3·76 (95% CI 3·04-4·66; I2=95%). Effect estimates were similar when stratified by tuberculosis type, sex, age, and country income category. Causes of mortality were extracted for 4226 deaths that occurred post-treatment, with most deaths attributable to cardiovascular disease (20% [95% CI 15-26]; I2=92%). INTERPRETATION:People treated for tuberculosis have significantly increased mortality following treatment compared with the general population or matched controls. These findings support the need for further research to understand and address the biomedical and social factors that affect the long-term prognosis of this population. FUNDING: None.
Authors: S G Mpagama; K S Msaji; O Kaswaga; L J Zurba; P M Mbelele; B W Allwood; B-S Ngungwa; R M Kisonga; M Lesosky; J Rylance; K Mortimer Journal: Int J Tuberc Lung Dis Date: 2021-10-01 Impact factor: 2.373
Authors: Khasan Safaev; Nargiza Parpieva; Irina Liverko; Sharofiddin Yuldashev; Kostyantyn Dumchev; Jamshid Gadoev; Oleksandr Korotych; Anthony D Harries Journal: Int J Environ Res Public Health Date: 2021-04-27 Impact factor: 3.390
Authors: Qing Hao Miow; Andres F Vallejo; Yu Wang; Jia Mei Hong; Chen Bai; Felicia Sw Teo; Alvin Dy Wang; Hong Rong Loh; Tuan Zea Tan; Ying Ding; Hoi Wah She; Suay Hong Gan; Nicholas I Paton; Josephine Lum; Alicia Tay; Cynthia Be Chee; Paul A Tambyah; Marta E Polak; Yee Tang Wang; Amit Singhal; Paul T Elkington; Jon S Friedland; Catherine Wm Ong Journal: J Clin Invest Date: 2021-08-02 Impact factor: 14.808
Authors: Moises A Huaman; Carlo N De Cecco; Marcio S Bittencourt; Eduardo Ticona; Cissy Kityo; Isabel Ballena; Sophie Nalukwago; Rashidah Nazzinda; Cesar Ticona; Ruben Azañero; Bin Zhang; Carey Farquhar; Thomas R Hawn; Timothy R Sterling; Carl J Fichtenbaum; Chris T Longenecker Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 9.079
Authors: Yvetot Joseph; Zhiwen Yao; Akanksha Dua; Patrice Severe; Sean E Collins; Heejung Bang; Marc Antoine Jean-Juste; Oksana Ocheretina; Alexandra Apollon; Margaret L McNairy; Kathryn Dupnik; Etienne Cremieux; Anthony Byrne; Jean W Pape; Serena P Koenig Journal: J Int AIDS Soc Date: 2021-07 Impact factor: 5.396
Authors: Giorgi Kuchukhidze; Davit Baliashvili; Natalia Adamashvili; Ana Kasradze; Russell R Kempker; Matthew J Magee Journal: Open Forum Infect Dis Date: 2021-03-15 Impact factor: 3.835